Resources from the same session
1967MO - Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
Presenter: Matthew Galsky
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast